May be miserable to you but not to patients, Doctors and investors who care about patient and not their own gain in stock market.
The news below shows BIIB is going ahead with another partner for MS and A2-73 is clearly out of picture.
“-- Alkermes plc (ALKS) and Biogen Inc. (BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). The NDA has been assigned a PDUFA (Prescription Drug User Fee Act) target action date in the fourth quarter of 2019”
Market Data 
Markets 
